Kornimate/medical-research-clean huggingface dataset:
age and number of previous anesthesia on the development of mild cognitive decline (mci)

Conditions: Mild Cognitive Impairment

Summary: mild cognitive impairment (mci), diagnosed with montreal cognitive assessment test (moca) define a condition that is insufficient to meet the threshold for a diagnosis of dementia, and it is an increasing health problem. it has been related to age and comorbilities, but the linkage between mci and number of previous anesthesia is still unclear.

mild cognitive impairment (mci) is a common neuropsychiatric term encompassing a greater-than-expected cognitive decline for patient's age and schooling and no more than mild functional impairment that is insufficient to meet the threshold for a diagnosis of dementia (dsm-v: "mild neurocognitive disorder") thus forming part of a declining cognitive trajectory. for the diagnosis of mci, the core clinical criteria are: concern about a change in cognition, impairment in one or more cognitive domains, preservation of independence in functional abilities and no presence of dementia. the montreal cognitive assessment (moca), a test that was developed specifically for detection of mci, has a sensitivity of 80 to 100% and specificity of 50 to 76% using a cut-off point of 25 to make diagnosis, and it has been suggested that it is better than mini mental status evaluation (mmse) in accurately differentiating individuals with mci from those with normal cognition. various risk factors have been proposed for mci, in particular the role of multiple biological, behavioural, social and environmental factors have been investigated. of them, increasing in age, lower educational level, sleep-disordered breathing and vascular risk factors (e.g. diabetes and hypertension) seem to be the most important. it has been estimated that mci is itself a risk factor both for dementia (it converts to dementia at a rate of 10% per year, for delirium and post-operative cognitive decline (pocd). hence, this study aims to investigate the incidence of mci in cardiac-surgery adult patients, enlisted for coronary artery by-pass grafting (cabg) or valve surgery, and to investigate the role of previous general anaesthesia in anamnesis as a risk factor for mci evenience.

Eligibility criteria:
inclusion criteria: * adults patients undergoing cardiac - surgery intervention with extracorporeal circulation exclusion criteria: * neurological disease before surgery
influences of propofol and sevoflurane anesthesia in brain tumor

Conditions: Brain Tumor

Summary: in the preoperative waiting area, the patients are randomly assigned and divided into two groups according to the allocation sequence table (corresponding to 1:1 randomization) generated by the computer. the propofol group was both induced and maintained at an effect-site concentration (ce) of 2.0-4.0 mcg/ml by a target-controlled infusion (tci) system. the sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3). the following patient data were recorded, the type of anesthesia, sex, age at the time of surgery, preoperative karnofsky performance status (kps) score and functional capacity, the postoperative complications within 30 days (according clavien-dindo classification), american society of anesthesiologists(asa) physical status scores, tumor size, intraoperative blood loss/transfusion, duration of surgery, duration of anesthesia, total opioid (remifentanil/fentanyl/ propofol) use, postoperative radiation therapy, postoperative chemotherapy, postoperative concurrent chemoradiotherapy, the presence of disease progression, and 6-month, 1-year, and 3-year overall survival and karnofsky performance status score were recorded.

during the operation, the dose of anesthetic drugs (propofol/ fentanyl /remifentanil and sevoflurane/ cisatracurium/ rocuronium) are adjusted to maintain the mean arterial pressure and heartbeat fluctuations within 20% of the baseline value and entropy (or bis) value at 40-60in both groups. the following patient data were recorded, the type of anesthesia, sex, age at the time of surgery, preoperative karnofsky performance status (kps) score and functional capacity, the postoperative complications within 30 days (according clavien-dindo classification), asa physical status scores, tumor size, intraoperative blood loss/transfusion, duration of surgery, duration of anesthesia, total opioid (remifentanil/ fentanyl/ propofol) use, postoperative radiation therapy, postoperative chemotherapy, postoperative concurrent chemoradiotherapy, the presence of disease progression, and 6-month, 1-year, and 3-year overall survival and karnofsky performance status score were recorded.

Eligibility criteria:
inclusion criteria: 1. twenty to eighty-year-old. 2. asa class i-iii. 3. patients undergoing elective craniotomy for primary brain tumors under general anesthesia. exclusion criteria: 1. severe mental disorder 2. poor liver function 3. pregnant or lactating women 4. morbidly obese 5. allergy to any of the drugs used in this study 6. recurrent tumor or repeat surgery 7. biopsy cases 8. incomplete outcome-data 9. palliative treatment after surgery 10. simultaneous treatment of other malignancies 11. emergency surgery 12. presence of other malignant tumors 13. combined propofol and inhalation anesthesia or other anesthetics, such as ketamine or dexmedetomidine 14. diagnosed as benign brain tumor 15. cerebellum tumor and pituitary gland tumor.

Keywords: primary brain tumor propofol sevoflurane survival
maternal voice on anesthetic emergence period

Conditions: Anesthesia, General

Summary: mother spend a large amount of time with their children. it is assumed that mother contributes to their neurological development not only with visual stimuli, but also with auditory stimuli. a recent study revealed that prefrontal cortex can be activated in response to the self-name being spoken by the mother than by a stranger. therefore, investigators suppose that recorded maternal voice can stimulate the pediatric patients and thereby fasten the emergence from general anesthesia.


Eligibility criteria:
inclusion criteria: * children aged between 2 and 8 years of american society of anesthesiologists physical status (asa ps) i or ii who are planned to receive an operation under general anesthesia exclusion criteria: * asa ps iii or iv * with developmental delay or neurological diseases associated with symptoms of agitation * refusal of consent * with developmental delay * with allergy or contraindication to use of ketamine (presence of an active upper respiratory tract infection (uri), increased intracranial pressure, open-globe injury, and a psychiatric or seizure disorder)

Keywords: emergence agitation emergence time pediatric
dismantling exposure, relaxation, and rescripting therapy

Conditions: Frequent Trauma-related Nightmares

Summary: the purpose of this case series dismantling study is to extend previous findings regarding the efficacy of a brief treatment for chronic post-trauma nightmares by examining the dose effect and mechanism of change. exposure, relaxation, and rescripting therapy (errt) is a promising psychological intervention developed to target trauma-related nightmares and sleep disturbances. errt has exhibited strong support in reducing the frequency and intensity of nightmares, as well as improving overall sleep quality in both civilian and veteran samples. in addition, significant decreases in ptsd and depression symptoms have been reported following treatment (davis et al., 2011; davis \& wright, 2007; long et al., 2011; swanson, favorite, horin, \& arnedt, 2009). errt is currently an evidence-level b suggested treatment (cranston, davis, rhudy, \& favorite, 2011). despite this evidence, the mechanism of change for errt remains unclear. we propose to conduct a set of case series in order to examine the possible mechanisms: psycho-education, dose response for exposure, and no exposure components of the treatment. each part of the treatment is theorized to contribute to the improved treatment outcome and it is hypothesized that participants will benefit no matter what group they are in. all participants will receive 5 to 6 treatment sessions, conducted once per week for about 90 minutes, of a modified version of errt.


Eligibility criteria:
inclusion criteria: * 18 years of age or older at the time of the intake, * experienced a traumatic event, as defined by the diagnostic and statistical manual (dsm-5), * have approximately one nightmare each week for the past month * be able to read and speak english. exclusion criteria: * age of 17 or younger * acute or apparent psychosis * unmedicated bipolar disorder * intellectual disability * active suicidality, * recent parasuicidal behaviors * untreated substance use disorder in past 6 months

Keywords: errt nightmares sleep trauma ptsd
effect of physiotherapy protocol in treatment of depression: longitudinal study

Conditions: Fibromyalgia; Depression

Summary: the purpose of his study is to investigate the effect of physiotherapy protocol in management of depression in patients with fibromyalgia and in patients with psychogenic depression.

this study will investigate the effect of physiotherapy protocol in management of depression in patients with fibromyalgia and in patients with psychogenic depression.

Eligibility criteria:
inclusion criteria: 1. fibromyalgia patients will be included if they meet the diagnosis of fm according to the american college rheumatology (acr), diagnosed with depression and referred by a physician. 2. patients diagnosed with mild and moderate forms of major depression. 3. their ages range from 20- 60 years old. 4. patients willing and able to participate in a physiotherapy program and capable of doing physical exercise on their own. exclusion criteria: 1. severe spinal injuries 2. severe musculoskeletal abnormalities 3. inflammatory rheumatic diseases 4. respiratory or cardiac pathologies 5. any vestibular, visual or neurological dysfunction affecting balance. 6. history of suicidal attempts 7. severe depression 8. suffering from severe somatic or psychiatric disorders.
home monitoring of patients with chronic diseases - an erehab test-retest study

Conditions: Arthritis, Rheumatoid

Summary: the aim of the study is to establish the intrarater-reliability, criterion validity and responsiveness of the adl-questionnaire applied on an ehealth platform to be used by patients diagnosed with rheumatoid arthritis. the study is designed as a repeated test-retest study including 240 patients filling in the adl-q, haq-di and pdq at day 1, 3, 56 and 58. the study provides an ehealth platform (a home-module in the danbio database) which makes it possible for the patients to complete their assessments and send information from their own home. intrarater reliability will be assessed by calculating the intraclass correlation coefficients (iccs). criterion validity will be evaluated based on correlational analysis and responsiveness based on effect sizes, in both cases involving haq-di. pdq scores will be used to classify participants based on pain phenotype to explore any relationship between pain phenotype and reliability.


Eligibility criteria:
inclusion criteria: * diagnosed with ra ≥ 12 months * das28-crp \< 5,1 * age between 18 and 85 years * computer and internet connection at home exclusion criteria: * blood samples (creatinine, haemoglobin) outside the reference limits +/- 5 % at screening * blood samples (thrombocytes and leukocytes) outside the reference limit -/+ 15 % at screening * blood samples (alat) outside the reference limit -/+ 100 % at screening * dementia or other linguistic/cognitive/physical deficiency that prevents participation * vision impairment that prevents the use of the devices and computer

Keywords: reproducibility of results
serological study of the exposure of personnel to covid-19

Conditions: Sars-CoV2

Summary: a seroconversion test for sars-cov-2 will be offered to all the employees of a care institution, which has treated 240 patients hospitalized for covid disease between 28/02 and 30/04/2020. the seroconversion test will be with a questionnaire to determine: * whether the subject has shown signs of infection in the last 3 recent months * if the subject has been in contact with covid-diagnosed subjects (rt-pcr diagnosis or scanner) outside of the activity or within the professional activity (patient or colleague) * working conditions during the period * the level of knowledge and respect of the barrier measures practices. * respect for distance during meals professional. overall seroprevalence and stratified seroprevalence by care and administrative areas will be determined.


Eligibility criteria:
inclusion criteria: * subject who worked at saint joseph saint luke's hospital during the epidemic wave (male or female). * free and informed consent * social security affiliation exclusion criteria: * subject refusal * subject on leave during the entire period
us & hilt comparative effect on neuropathic pain, strength & qof in diabetic foot

Conditions: Diabetic Foot; Diabetic Neuropathies

Summary: to compare the effects of therapeutic ultrasound and high intensity laser therapy on neuropathic pain , strength and quality of life in patients with diabetic foot

therapeutic ultrasound and laser therapy with routine physical therapy are used to improve neuropathic pain and foot related quality of life. the scarcity of evidence regarding the application of high intensity laser therapy necessitates a comprehensive investigation. the effects of hilt and comparative effects with ultrasound remains largely unexplored in diabetic peripheral neuropathy

Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes. * diabetic patients of age 50 to 75 years. * diabetic patient of both genders * diagnosed diabetes mellitus with at least 7 years of duration * distal symmetrical or asymmetrical polyneuropathy with pain in the lower extremity for ≥6 months * dns (diabetic neuropathy symptoms questionnaire) score greater than 4 (90 percent probability of neuropath exclusion criteria: * pregnant females * lower limb amputated patients * history or evidence of neurological disorders other than peripheral neuropathy associated with diabetes mellitus. * evidence of musculoskeletal dysfunctions like scoliosis, lumbar disc prolapses and lumbar spine associated radiculopathy. * history of any low back surgeries and lower limb surgeries * patient with malignancy. patient with epilepsy * patient with hemophilia * patient with pacemaker, metal implants prosthesis and internal fixation screws. * patient with severe cervical and lumbar neuropathy, rheumatoid arthritis, hereditary neuropathy * patient with a history of neurosurgery

Keywords: diabetic neuropathies
tofacitinib bioequivalence study comparing tablets and capsules

Conditions: Healthy

Summary: the overall aim of the study is to establish bioequivalence between commercial tofacitinib tablet formulations with the tofacitinib capsule formulation.


Eligibility criteria:
inclusion criteria: * healthy male and/or female (non-childbearing potential) subjects between the ages of 21 and 55 years, inclusive. healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including oral temperature, bp and pr measurement, 12 lead ecg and clinical laboratory tests. exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
gos and the management of hyperuricemia

Conditions: Subjects With Hyperuricemia

Summary: hyperuricemia is a major risk factor for many chronic diesease. recently, gut mcirobiota has been identified as a novel therapeutic target for hyperuricemia. both annimal studies and pilot human trials have demonstrated that administration of prebiotics help delay the progression of hyperuricemia throuh several mechanisms. this trial aims to examine the protective effects and potential mechanisms of galactooligosaccharide on hyperuricemia in clinical trials.

hyperuricemia is a major risk factor for many chronic diseases. recently, dysbiosis of gut microbiota has been reported to play an important role in the pathogenesis of hyperuricemia. animal studies have demonstrated that administration of prebiotics help delay the progression of hyperuricemia through several mechanisms such as reduction in endotoxemia, and enhanced production of short-chain fatty acids and hippuric acid. however, whether administration of galactooligosaccharide also has a protective effect in subjects with hyperuricemia remain under-explored. moreover, the molecular mechanisms underlying the protective effect of galactooligosaccharide remains largely unknown.

Eligibility criteria:
inclusion criteria: * local residents aged between 18-80 years old; * stable weight (\<5% weight change over the past 3 months); * fasting uric acid \> 420 umol/l for male and \> 360 umol/l for female on two different days; * not taking uric acid lowering drugs or have stopped taking uric acid lowering drugs for over 4 weeks at the time of recruitment; * absence of any diet or medication that might interfere with uric acid metabolism or gut microbiota, especially antibiotics, prebiotics or probiotics at the least 4 weeks before recruitment exclusion criteria: * acute illness or evidence of any acute or chronic inflammatory of infective diseases; * participation in regular diet program more than 2 times per week in the latest 3 months prior to recruitment; * mental illness rendering them unable to understand the nature, scope, and possible consequences of the study; * women of childbearing age who are pregnant, breast-feeding or preparing for pregnancy; patients who had surgey within the past 6 months or planned surgery during the trial period.
safety, tolerability, pharmacokinetics, and pharmacodynamics of hrs9531 in healthy subjects

Conditions: Type 2 Diabetes

Summary: the study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple subcutaneous injections of hrs9531 in healthy subjects.


Eligibility criteria:
inclusion criteria: 1. ability to understand the trial procedures and possible adverse events, be able and willing to provide a written informed consent; 2. age 18-55 years on the date of signing informed consent (inclusive); 3. body weight ≥50 kg, body mass index (bmi) within the range of 19.0-35.0 kg/m2 (inclusive); 4. subjects with good general health, no clinically significant abnormalities. exclusion criteria: 1. with previous major organ diseases, including but not limited to neuropsychiatric, cardiovascular, digestive, respiratory, urinary, endocrine, blood, immune and other diseases, are judged by researchers to be unsuitable for the study; 2. had a severe trauma or major surgery within 6 months prior to screening, planned to undergo surgery during the trial period; 3. participants in clinical trials of any drug or medical device in the 3 months prior to screening; 4. blood donation history or blood loss ≥400 ml within 1 month before screening, or received blood transfusion within 2 months; 5. allergic constitution includes severe drug allergy or history of drug allergy; 6. hepatitis b surface antigen (hbsag), hiv antibody detection, treponema pallidum specific antibody detection, hepatitis c virus antibody (hcvab) positive; 7. breast-feeding women; 8. the investigator considers that the subject has any other factors that would make it inappropriate to participate in this study.
effect of caffeine on cold-stimulated brown adipose tissue activity

Conditions: Brown Adipose Tissue (BAT) Physiology; Cold Exposure

Summary: the purpose of the study is to asses brown adipose tissue activity after a cold mild stimulus, preceded by 200mg caffeine or placebo administration.

brown adipose tissue (bat) activation is typically through beta3-adrenoceptors (beta3-ar), but beta3-alone are less efficacious than cold in activating human bat. recent research suggests that adenosine, released during cold exposure, plays a key role in bat thermogenesis. this study aims to investigate the role of the adenosine a2a receptor (a2ar) in bat activation through a randomized trial with mild cold exposure and caffeine, a potent a2ar antagonist, to explore new therapeutic strategies for metabolic diseases. this is a randomized, double-blind, placebo-controlled cross-over trial involving healthy volunteers. the study includes a screening visit and two main study visits (a and b), which will occur in random order. during the two study visits, resting energy expenditure will be assessed by indirect calorimetry under warm conditions and following mild cold exposure, after administration of either caffeine or placebo. for cold exposure, participants will wear cooling sleeves around the waist, which gradually lower the surface body temperature to 10°c or to the lowest tolerable temperature without inducing shivering. additionally, bat activity will be assessed using 18f-fdg pet/ct, performed 30 minutes after the injection of 75 mbq of 18f-fdg.

Eligibility criteria:
inclusion criteria: * bmi 18.5 to 25 kg/m2 * able to give informed consent as documented by signature * moderate caffeine consumption (1 to 3 cups of coffee per day) * increase of ee in response to mild cold of ≥ 5% of ree exclusion criteria: * known hypersensitivity or allergy to caffeine * concomitant medication other than prescription free analgesics (paracetamol and nsaid) and oral contraceptives * other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, cardiac arrhythmia, hypertension, diabetes mellitus, hyper- or hypothyroidism) * history of depressive disorder or anxiety disorder * smoker / habitual tobacco use * habitual excessive alcohol use * regular consumption of caffeine containing energy drinks * weight change of \>5% within 3 months prior to inclusion * systolic blood pressure \>140 mmhg and/or diastolic blood pressure \> 95 mmhg. * resting heart rate \>90 bpm * hypersensitivity to cold (e.g. raynaud syndrome) * known or suspected non-compliance, drug or alcohol abuse * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant. * enrolment of the investigator, his/her family members, employees, and other dependent persons * enrolment into another study using ionizing radiation within the previous 12 months. * pregnancy or lactation